Research programme: diabetes therapy - BiovitrumAlternative Names: BVT 24834; BVT 3776; Diabetes therapy research programme - Biovitrum
Latest Information Update: 08 Sep 2005
At a glance
- Originator Biovitrum
- Mechanism of Action Fatty acid-binding protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 08 Sep 2005 Discontinued - Preclinical for Type-2 diabetes mellitus in Sweden (unspecified route)
- 07 Sep 2004 Preclinical trials in Type-2 diabetes mellitus in Sweden (unspecified route)